Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,1.4253830985176687e-08,7.538146551724138,136.18596570313542,"['SNAP25', 'GABRA1', 'CEBPB', 'TSPYL1', 'CHRNA4', 'ATP1A3', 'YWHAZ', 'PRKAR1A', 'PRKAR2B', 'PLP1', 'HES1', 'SLC25A4', 'YWHAG', 'HES5', 'YWHAH']",4.418687605404773e-06,0,0,15
2,Calcium Regulation in the Cardiac Cell WP536,4.308169102075864e-07,6.090617062602719,89.27372292003481,"['ITPR1', 'CACNA1A', 'ATP1B1', 'YWHAZ', 'RGS4', 'FKBP1A', 'GNG2', 'PRKAR1A', 'PRKAR2B', 'GJA9', 'PRKCQ', 'CALM3', 'YWHAG', 'YWHAH']",6.67766210821759e-05,0,0,14
3,Myometrial relaxation and contraction pathways WP289,1.46965649601634e-05,5.073705613245226,56.45967229371773,"['RGS4', 'ACTA2', 'GNG2', 'PRKAR1A', 'PRKAR2B', 'ITPR1', 'PRKCQ', 'CALM3', 'YWHAZ', 'ETS2', 'YWHAG', 'YWHAH']",0.0015186450458835512,0,0,12
4,mBDNF and proBDNF regulation of GABA neurotransmission WP4829,8.924025535334148e-05,9.795150501672241,91.3317300172149,"['GABRB2', 'GABRA1', 'SLC12A5', 'GABRA4', 'GABRD', 'GABRG2']",0.005692189594415492,0,0,6
5,Synaptic Vesicle Pathway WP2267,9.180950958734665e-05,7.636185682326622,70.98441420634236,"['SNAP25', 'STX1B', 'SYT1', 'CACNA1A', 'SYP', 'CPLX2', 'SLC25A4']",0.005692189594415492,0,0,7
6,GABA receptor Signaling WP4159,0.0003529544772614095,9.765833333333333,77.63028370381893,"['GABRB2', 'GABRA1', 'GABRA4', 'GABRD', 'GABRG2']",0.01823598132517282,0,0,5
7,Apoptosis Modulation and Signaling WP1772,0.0009297272189491444,4.990115924344113,34.83409966943678,"['CAPNS1', 'IL1R1', 'TOLLIP', 'CYCS', 'TNFRSF11B', 'MAP3K14', 'HSPA1A']",0.04117363398203354,0,0,7
8,Fragile X Syndrome  WP4549,0.0018855643682479,3.5035456248327534,21.97959193855496,"['GABRB2', 'GABRA1', 'GRIN2A', 'GRM5', 'PRKAR1A', 'ITPR1', 'GABRD', 'GABRG2', 'GRM1']",0.07306561926960613,0,0,9
9,Parkin-Ubiquitin Proteasomal System pathway WP2359,0.0030785211668652598,4.598858941569939,26.5966082244804,"['PSMD10', 'TUBB3', 'TUBB4A', 'HSPA1B', 'SNCA', 'HSPA1A']",0.10603795130313672,0,0,6
10,Extracellular vesicles in the crosstalk of cardiac cells WP4300,0.0038085416435449998,11.651324503311258,64.903807236788,"['EGF', 'HSPB1', 'ETS2']",0.11278300552295563,0,0,3
11,IL-18 signaling pathway WP4754,0.004001977615330683,2.7249390322166605,15.044297482566053,"['ACTA2', 'SOCS3', 'CEBPB', 'NRN1', 'TMSB4X', 'STMN1', 'CYCS', 'HSPB1', 'TNFRSF11B', 'CDK5R2', 'PTMS']",0.11278300552295563,0,0,11
12,Prolactin Signaling Pathway WP2037,0.004694988764756442,4.186454849498328,22.44467108165127,"['SOCS3', 'PAK1', 'IRS2', 'HRAS', 'YWHAZ', 'YWHAG']",0.11344066186445761,0,0,6
13,ERK Pathway in Huntington's Disease WP3853,0.004757189045928868,10.591210114388922,56.64283303799905,"['EGF', 'HRAS', 'GRM1']",0.11344066186445761,0,0,3
14,Vitamin D Receptor Pathway WP2877,0.005490736090688728,4.041402375735209,21.03425846926278,"['BCL6', 'CREG2', 'S100A6', 'PRKCQ', 'TNFRSF11B', 'ATP2C2']",0.1215805848652504,0,0,6
15,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,0.005906354304949341,4.755284552845528,24.402819787123235,"['CEBPB', 'WNT7B', 'TNFRSF11B', 'HES1', 'HES5']",0.12206465563561972,0,0,5
16,Alzheimer's disease WP2059,0.006380902105956904,3.9060200668896323,19.742766705021417,"['GRIN2A', 'ITPR1', 'CYCS', 'CALM3', 'SNCA', 'CDK5R1']",0.12362997830291501,0,0,6
17,Complement and Coagulation Cascades WP558,0.008402147954559907,8.31953642384106,39.761293347925125,"['C1R', 'PROS1', 'SERPING1']",0.13708767715334583,0,0,3
18,Globo Sphingolipid Metabolism WP1424,0.008402147954559907,8.31953642384106,39.761293347925125,"['ST6GAL1', 'ST6GAL2', 'FUT2']",0.13708767715334583,0,0,3
19,Monoamine Transport WP727,0.008402147954559907,8.31953642384106,39.761293347925125,"['IL1R1', 'TNFRSF11B', 'AMPH']",0.13708767715334583,0,0,3
20,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.009138358746666974,4.236594202898551,19.891972633829123,"['PAK1', 'TMSB4X', 'NEFL', 'NEFM', 'PFN2']",0.1416445605733381,0,0,5
21,Differentiation Pathway WP2848,0.00989624251568991,7.764238410596026,35.8366198775198,"['EGF', 'HGF', 'WNT7B']",0.14608738951732725,0,0,3
22,PKC-gamma calcium signaling pathway in ataxia WP4760,0.011534889648536908,7.278352649006623,32.47876768119511,"['ITPR1', 'CACNA1A', 'GRM1']",0.16253708141120188,0,0,3
23,TGF-beta Receptor Signaling WP560,0.01380082712460556,4.7139836907278765,20.190118256112445,"['FKBP1A', 'EGF', 'SMAD9', 'HRAS']",0.18601114820120537,0,0,4
24,Intracellular trafficking proteins involved in CMT neuropathy WP4856,0.015254315393010611,6.468543046357616,27.057222389754113,"['HSPB1', 'NEFL', 'NDRG1']",0.19218096452635264,0,0,3
25,T-cell receptor (TCR) signaling pathway WP69,0.01655018987484277,3.6064814814814814,14.791470609939115,"['PAK1', 'ITPR1', 'PRKCQ', 'HRAS', 'MAP3K14']",0.19218096452635264,0,0,5
26,Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.01733819251238489,6.12757058208435,24.846340058693126,"['ITPR1', 'P3H2', 'TNFRSF11B']",0.19218096452635264,0,0,3
27,MAPK Signaling Pathway WP382,0.019403679692035422,2.24,8.830735325555736,"['PAK1', 'IL1R1', 'EGF', 'STMN1', 'CACNA1A', 'HSPB1', 'HRAS', 'MAP3K14', 'HSPA1B', 'HSPA1A']",0.19218096452635264,0,0,10
28,TGF-beta receptor signaling in skeletal dysplasias WP4816,0.019565483297758687,4.202927179671366,16.534266440794738,"['FKBP1A', 'EGF', 'SMAD9', 'HRAS']",0.19218096452635264,0,0,4
29,Pathogenic Escherichia coli infection WP2272,0.019565483297758687,4.202927179671366,16.534266440794738,"['TUBB3', 'ARPC5L', 'YWHAZ', 'TUBB4A']",0.19218096452635264,0,0,4
30,Lung fibrosis WP3624,0.019572875024912787,5.820695364238411,22.89634897574483,"['CEBPB', 'EGF', 'HGF']",0.19218096452635264,0,0,3
31,Ras signaling WP4223,0.019795151949155314,2.502680134680135,9.816307896882458,"['GRIN2A', 'PAK1', 'GNG2', 'PLCE1', 'CALM3', 'PAK3', 'HRAS', 'ETS2']",0.19218096452635264,0,0,8
32,"GPCRs, Class C Metabotropic glutamate, pheromone WP501",0.02045797364312786,11.062706270627062,43.027096871762105,"['GRM5', 'GRM1']",0.19218096452635264,0,0,2
33,Nicotine Activity on Dopaminergic Neurons WP1602,0.02045797364312786,11.062706270627062,43.027096871762105,"['GNG2', 'CHRNA4']",0.19218096452635264,0,0,2
34,Exercise-induced Circadian Regulation WP410,0.021206204232729908,4.091974121349886,15.768264685005699,"['DNAJA1', 'CEBPB', 'TUBB3', 'ERC2']",0.1933506856513609,0,0,4
35,Signal transduction through IL1R WP4496,0.021958897148240415,5.543046357615894,21.16658194939358,"['IL1R1', 'TOLLIP', 'MAP3K14']",0.19449308902727225,0,0,3
36,EGF/EGFR signaling pathway WP437,0.024090468581006094,2.405387205387205,8.962326025781616,"['PLSCR1', 'PAK1', 'EGF', 'LIMK2', 'CFL1', 'STMN1', 'PLCE1', 'HRAS']",0.2074457016697747,0,0,8
37,Serotonin and anxiety WP3947,0.025149803258303426,9.679042904290428,35.646997493550444,"['GABRA1', 'GRM1']",0.21071456783983952,0,0,2
38,Structural Pathway of Interleukin 1 (IL-1) WP2637,0.02859608361371578,3.700996677740864,13.155139052915715,"['IL1R1', 'TOLLIP', 'IRF7', 'MAP3K14']",0.23328384000662872,0,0,4
39,Vitamin D-sensitive calcium signaling in depression WP4698,0.03002508199184886,4.8489238410596025,16.99897985986734,"['GRIN2A', 'GRM5', 'ITPR1']",0.234295594248641,0,0,3
40,Leptin Insulin Overlap WP3935,0.030231689580469807,8.602860286028603,30.100243149217995,"['SOCS3', 'IRS2']",0.234295594248641,0,0,2
41,Hippo-Merlin Signaling Dysregulation WP4541,0.03203600085052479,2.993333333333333,10.299745646035197,"['PAK1', 'PRKAR1A', 'PRKAR2B', 'PAK3', 'HRAS']",0.23801475620943177,0,0,5
42,The influence of laminopathies on Wnt signaling WP4844,0.03301495005485666,4.654569536423841,15.875781515861748,"['CEBPB', 'HES1', 'HES5']",0.23801475620943177,0,0,3
43,Glycolysis and Gluconeogenesis WP534,0.03301495005485666,4.654569536423841,15.875781515861748,"['TPI1', 'MDH1', 'ENO2']",0.23801475620943177,0,0,3
44,Differentiation of white and brown adipocyte WP2895,0.03568100429012715,7.741914191419142,25.804859283705763,"['CEBPB', 'SMAD9']",0.25138889386225943,0,0,2
45,Senescence and Autophagy in Cancer WP615,0.037431460194201474,2.8605392156862743,9.397568569932831,"['GABARAPL1', 'CEBPB', 'MAP1LC3A', 'IRF7', 'HRAS']",0.2578611702267213,0,0,5
46,G Protein Signaling Pathways WP35,0.041319814061581736,2.7783333333333333,8.852917825915235,"['PRKAR1A', 'PRKAR2B', 'ITPR1', 'PRKCQ', 'HRAS']",0.2666630966340914,0,0,5
47,Signaling of Hepatocyte Growth Factor Receptor WP313,0.04287353920948635,4.154801324503311,13.085548620377487,"['PAK1', 'HGF', 'HRAS']",0.2666630966340914,0,0,3
48,Complement system WP2806,0.04287353920948635,4.154801324503311,13.085548620377487,"['C1R', 'PROS1', 'SERPING1']",0.2666630966340914,0,0,3
49,MET in type 1 papillary renal cell carcinoma WP4205,0.04479743527265799,3.1703844328429045,9.845959811287058,"['PAK1', 'HGF', 'PAK3', 'HRAS']",0.2666630966340914,0,0,4
50,Oncostatin M Signaling Pathway WP2374,0.04479743527265799,3.1703844328429045,9.845959811287058,"['SOCS3', 'CEBPB', 'OSMR', 'HRAS']",0.2666630966340914,0,0,4
51,Metapathway biotransformation Phase I and II WP702,0.04544385446620193,2.7006944444444443,8.348596464081613,"['CYP39A1', 'HS3ST3B1', 'CHST6', 'KCNAB1', 'SULT4A1']",0.2666630966340914,0,0,5
52,Disruption of postsynaptic signaling by CNV WP4875,0.04645099102658366,4.0111897693537335,12.31177531668583,"['GRIN2A', 'GRM1', 'YWHAG']",0.2666630966340914,0,0,3
53,NO/cGMP/PKG mediated Neuroprotection WP4008,0.04645099102658366,4.0111897693537335,12.31177531668583,"['GRIN2A', 'NEFL', 'CYCS']",0.2666630966340914,0,0,3
54,Parkinson's disease pathway WP2371,0.04645099102658366,4.0111897693537335,12.31177531668583,"['UCHL1', 'CYCS', 'SNCA']",0.2666630966340914,0,0,3
55,Transcription factor regulation in adipogenesis WP3599,0.04759582221975269,6.4504950495049505,19.641823801912228,"['CEBPB', 'IRS2']",0.26826736160224246,0,0,2
56,Fas ligand pathway and stress induction of heat shock proteins WP314,0.050171001435198335,3.8771523178807947,11.601672979119554,"['PAK1', 'HSPB1', 'CYCS']",0.27773232937341935,0,0,3
57,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.05402039553179145,5.9537953795379535,17.375518383112464,"['ITPR1', 'PRKCQ']",0.28878875275193544,0,0,2
58,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.05403144406326534,3.751762443922239,10.948352286223672,"['ACTA2', 'PAK1', 'PAK3']",0.28878875275193544,0,0,3
59,Melanoma WP4685,0.055942290706732796,2.930107189870244,8.4487725780817,"['GRIN2A', 'PAK1', 'CALM3', 'HRAS']",0.2939340698150367,0,0,4
60,Serotonin Receptor 2 and ELK-SRF/GATA4 signaling WP732,0.06073047967447644,5.528052805280528,15.48578723036582,"['ITPR1', 'HRAS']",0.3058877923764518,0,0,2
61,Apoptosis Modulation by HSP70 WP384,0.06073047967447644,5.528052805280528,15.48578723036582,"['CYCS', 'HSPA1A']",0.3058877923764518,0,0,2
62,NRF2 pathway WP2884,0.061749553947235004,2.459915611814346,6.850049583361036,"['SLC6A17', 'HGF', 'SLC5A3', 'EPHA3', 'HSPA1A']",0.3058877923764518,0,0,5
63,Common Pathways Underlying Drug Addiction WP2636,0.062164293289407944,3.5237808549066827,9.788973382993158,"['GRIN2A', 'GRM5', 'GRM1']",0.3058877923764518,0,0,3
64,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,0.07082941559557161,3.3218543046357616,8.79454579106805,"['PAK1', 'PRKCQ', 'MAP3K14']",0.34307998179105,0,0,3
65,Urea cycle and associated pathways WP4595,0.07493402816194639,4.836221122112211,12.53136070814997,"['MDH1', 'GLS2']",0.34352887840460106,0,0,2
66,Gastric Cancer Network 2 WP2363,0.07493402816194639,4.836221122112211,12.53136070814997,"['S100A6', 'CACYBP']",0.34352887840460106,0,0,2
67,Splicing factor NOVA regulated synaptic proteins WP4148,0.07535472171455765,3.2293046357615895,8.349524377417225,"['EPB41L3', 'GRIK2', 'GABRG2']",0.34352887840460106,0,0,3
68,Regulation of Microtubule Cytoskeleton WP2038,0.07535472171455765,3.2293046357615895,8.349524377417225,"['PAK1', 'PARD6A', 'STMN1']",0.34352887840460106,0,0,3
69,Cannabinoid receptor signaling WP3869,0.08239275861033751,4.551349252572316,11.361340739422072,"['PRKAR2B', 'PRKAR1A']",0.35974303055217793,0,0,2
70,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.08239275861033751,4.551349252572316,11.361340739422072,"['BCL6', 'H2AFZ']",0.35974303055217793,0,0,2
71,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) WP2817,0.08239275861033751,4.551349252572316,11.361340739422072,"['CEBPB', 'ATP2C2']",0.35974303055217793,0,0,2
72,Genotoxicity pathway WP4286,0.08477616342355403,3.0588184036249566,7.5483711805846,"['ACTA2', 'ITPKC', 'ITPR1']",0.36500848140696873,0,0,3
73,Toll-like Receptor Signaling related to MyD88 WP3858,0.09006748132617746,4.298129812981298,10.346441310606641,"['TOLLIP', 'IRF7']",0.37730971906912186,0,0,2
74,Extracellular vesicle-mediated signaling in recipient cells WP2870,0.09006748132617746,4.298129812981298,10.346441310606641,"['HGF', 'HRAS']",0.37730971906912186,0,0,2
75,Nuclear Receptors Meta-Pathway WP2882,0.09375827045933763,1.77993265993266,4.213163615302415,"['SLC6A17', 'HGF', 'ENC1', 'IRS2', 'HES1', 'SLC5A3', 'EPHA3', 'HSPA1A']",0.38114487396150565,0,0,8
76,Synaptic signaling pathways associated with autism spectrum disorder WP4539,0.0946714686936643,2.905380794701987,6.848977931501402,"['GRIN2A', 'HRAS', 'GRM1']",0.38114487396150565,0,0,3
77,IL-4 signaling pathway WP395,0.0946714686936643,2.905380794701987,6.848977931501402,"['SOCS3', 'CEBPB', 'IRS2']",0.38114487396150565,0,0,3
78,Spinal Cord Injury WP2431,0.09732406710984567,2.3867109634551493,5.560341942363889,"['FKBP1A', 'VCAN', 'IL1R1', 'GFAP']",0.382686767751854,0,0,4
79,Osteoblast Signaling WP322,0.09752340210450473,12.868421052631579,29.953346371236453,['TNFRSF11B'],0.382686767751854,0,0,1
80,Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,0.10600300229752187,3.8676567656765677,8.680135132467116,"['NOD1', 'NLRP1']",0.40040340933419416,0,0,2
81,Breast cancer pathway WP4262,0.11323848753815129,2.021354166666667,4.403033259624833,"['EGF', 'WNT7B', 'HES1', 'HRAS', 'HES5']",0.40040340933419416,0,0,5
82,MTHFR deficiency WP4288,0.1142344494282557,3.6831683168316833,7.990642386982849,"['GRIN2A', 'CYCS']",0.40040340933419416,0,0,2
83,Regucalcin in proximal tubule epithelial kidney cells WP4838,0.1142344494282557,3.6831683168316833,7.990642386982849,"['ACTA2', 'PRKCQ']",0.40040340933419416,0,0,2
84,Serotonin Transporter Activity WP1455,0.12038510703828564,9.650493421052632,20.43066828892987,['IL1R1'],0.40040340933419416,0,0,1
85,Arachidonate Epoxygenase / Epoxide Hydrolase WP678,0.12038510703828564,9.650493421052632,20.43066828892987,['COX8A'],0.40040340933419416,0,0,1
86,NAD Biosynthesis II (from tryptophan) WP2485,0.12038510703828564,9.650493421052632,20.43066828892987,['HAAO'],0.40040340933419416,0,0,1
87,PTF1A related regulatory pathway WP4147,0.12038510703828564,9.650493421052632,20.43066828892987,['HES1'],0.40040340933419416,0,0,1
88,Integrin-mediated Cell Adhesion WP185,0.12213861229075337,2.183894062046699,4.59185284392504,"['PAK1', 'CAPNS1', 'PAK3', 'HRAS']",0.40040340933419416,0,0,4
89,Resistin as a regulator of inflammation WP4481,0.13115590490958437,3.36231884057971,6.830108746452342,"['ITPR1', 'PLCE1']",0.40040340933419416,0,0,2
90,IL-1 signaling pathway WP195,0.13265896885616021,2.4711850077497535,4.9917284460897156,"['IL1R1', 'TOLLIP', 'MAP3K14']",0.40040340933419416,0,0,3
91,"Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",0.13265896885616021,2.4711850077497535,4.9917284460897156,"['PLCE1', 'PRKCQ', 'HRAS']",0.40040340933419416,0,0,3
92,Regulatory circuits of the STAT3 signaling pathway WP4538,0.13265896885616021,2.4711850077497535,4.9917284460897156,"['SOCS3', 'STMN1', 'OSMR']",0.40040340933419416,0,0,3
93,TGF-beta Signaling Pathway WP366,0.13515706348698775,1.901470588235294,3.805446827113178,"['EID2', 'KLF6', 'PARD6A', 'LIMK2', 'PJA1']",0.40040340933419416,0,0,5
94,ESC Pluripotency Pathways WP3931,0.13546404441333257,2.0948190715632578,4.187646030433046,"['EGF', 'WNT7B', 'SMAD9', 'HRAS']",0.40040340933419416,0,0,4
95,Focal Adhesion WP306,0.1379551144812446,1.764518090605047,3.4952049066678823,"['PAK1', 'EGF', 'HGF', 'PAK3', 'HRAS', 'MYL12B']",0.40040340933419416,0,0,6
96,Insulin Signaling WP481,0.1379551144812446,1.764518090605047,3.4952049066678823,"['SOCS3', 'SNAP25', 'IRS2', 'PRKCQ', 'MAP3K14', 'HRAS']",0.40040340933419416,0,0,6
97,Kisspeptin/kisspeptin receptor system in the ovary WP4871,0.13982012547293426,3.2219471947194718,6.338854079612426,"['PRKCQ', 'HRAS']",0.40040340933419416,0,0,2
98,Oxidative Damage WP3941,0.13982012547293426,3.2219471947194718,6.338854079612426,"['C1R', 'CYCS']",0.40040340933419416,0,0,2
99,Proximal tubule transport WP4917,0.13982012547293426,3.2219471947194718,6.338854079612426,"['ATP1B1', 'ATP6V0C']",0.40040340933419416,0,0,2
100,Renin-angiotensin-aldosterone system (RAAS) WP4756,0.13982012547293426,3.2219471947194718,6.338854079612426,"['ITPR1', 'CALM3']",0.40040340933419416,0,0,2
101,Sulfation Biotransformation Reaction WP692,0.1426695280068637,7.719736842105263,15.032059293200867,['SULT4A1'],0.40040340933419416,0,0,1
102,BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation WP3876,0.1426695280068637,7.719736842105263,15.032059293200867,['SMAD9'],0.40040340933419416,0,0,1
103,Urea cycle and related diseases WP4571,0.1426695280068637,7.719736842105263,15.032059293200867,['GLS2'],0.40040340933419416,0,0,1
104,Complement Activation WP545,0.1426695280068637,7.719736842105263,15.032059293200867,['C1R'],0.40040340933419416,0,0,1
105,Farnesoid X receptor pathway WP2879,0.1426695280068637,7.719736842105263,15.032059293200867,['IRS2'],0.40040340933419416,0,0,1
106,Folate-Alcohol and Cancer Pathway Hypotheses WP1589,0.1426695280068637,7.719736842105263,15.032059293200867,['CEBPB'],0.40040340933419416,0,0,1
107,Genes targeted by miRNAs in adipocytes WP1992,0.1426695280068637,7.719736842105263,15.032059293200867,['TMSB4X'],0.40040340933419416,0,0,1
108,HIF1A and PPARG regulation of glycolysis WP2456,0.1426695280068637,7.719736842105263,15.032059293200867,['TPI1'],0.40040340933419416,0,0,1
109,Mammary gland development pathway - Involution (Stage 4 of 4) WP2815,0.1426695280068637,7.719736842105263,15.032059293200867,['SOCS3'],0.40040340933419416,0,0,1
110,Regulation of Actin Cytoskeleton WP51,0.14285584971486345,1.8645833333333333,3.628328510369903,"['PAK1', 'EGF', 'TMSB4X', 'CFL1', 'PAK3']",0.40040340933419416,0,0,5
111,RAC1/PAK1/p38/MMP2 Pathway WP3303,0.1443587653592714,2.369914853358562,4.5868603572854845,"['PAK1', 'STMN1', 'HRAS']",0.40040340933419416,0,0,3
112,ErbB signaling pathway WP673,0.14466187692074112,2.039342542402518,3.9427754319143253,"['PAK1', 'EGF', 'PAK3', 'HRAS']",0.40040340933419416,0,0,4
113,IL17 signaling pathway WP2112,0.14860373370517943,3.0928052805280526,5.89634673415487,"['CEBPB', 'MAP3K14']",0.40058397781396193,0,0,2
114,Lipid Metabolism Pathway WP3965,0.14860373370517943,3.0928052805280526,5.89634673415487,"['PRKAR2B', 'PRKAR1A']",0.40058397781396193,0,0,2
115,Neural Crest Cell Migration during Development WP4564,0.14860373370517943,3.0928052805280526,5.89634673415487,"['PAK1', 'PAK3']",0.40058397781396193,0,0,2
116,Alpha 6 Beta 4 signaling pathway WP244,0.15749518297750853,2.9735973597359737,5.496279621498363,"['IRS2', 'HRAS']",0.4109779858910559,0,0,2
117,Bladder cancer WP2828,0.15749518297750853,2.9735973597359737,5.496279621498363,"['EGF', 'HRAS']",0.4109779858910559,0,0,2
118,Prader-Willi and Angelman Syndrome WP3998,0.15749518297750853,2.9735973597359737,5.496279621498363,"['GABRD', 'GABRG2']",0.4109779858910559,0,0,2
119,Thyroid stimulating hormone (TSH) signaling pathway WP2032,0.1625101014726355,2.232615894039735,4.05669682821862,"['GNG2', 'HRAS', 'MYL12B']",0.4109779858910559,0,0,3
120,Transcriptional cascade regulating adipogenesis WP4211,0.16439119435642235,6.432565789473684,11.614038444678513,['CEBPB'],0.4109779858910559,0,0,1
121,Gene regulatory network modelling somitogenesis  WP2854,0.16439119435642235,6.432565789473684,11.614038444678513,['HES1'],0.4109779858910559,0,0,1
122,Glial Cell Differentiation WP2276,0.16439119435642235,6.432565789473684,11.614038444678513,['PLP1'],0.4109779858910559,0,0,1
123,MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma WP3593,0.16439119435642235,6.432565789473684,11.614038444678513,['HES1'],0.4109779858910559,0,0,1
124,Osteoclast Signaling WP12,0.16439119435642235,6.432565789473684,11.614038444678513,['TNFRSF11B'],0.4109779858910559,0,0,1
125,Adipogenesis WP236,0.16866810210083755,1.9126368893810755,3.404153955681573,"['SOCS3', 'CEBPB', 'KLF6', 'IRS2']",0.4182968932100771,0,0,4
126,Neural Crest Cell Migration in Cancer WP4565,0.17555792370322526,2.7607260726072607,4.80307323612526,"['PAK1', 'PAK3']",0.42929047838551226,0,0,2
127,Neural Crest Differentiation WP2064,0.18130086993868674,2.110295003010235,3.6035341820703577,"['HES1', 'HES5', 'GFAP']",0.42929047838551226,0,0,3
128,Proteasome Degradation WP183,0.18130086993868674,2.110295003010235,3.6035341820703577,"['PSMD10', 'UCHL1', 'H2AFZ']",0.42929047838551226,0,0,3
129,Aryl Hydrocarbon Receptor Netpath WP2586,0.18470857414986716,2.665301012859907,4.501629365720985,"['KLF6', 'HRAS']",0.42929047838551226,0,0,2
130,Mitochondrial CIV Assembly WP4922,0.18470857414986716,2.665301012859907,4.501629365720985,"['COX8A', 'COA3']",0.42929047838551226,0,0,2
131,Biomarkers for urea cycle disorders WP4583,0.18556427130212466,5.5131578947368425,9.28610944744807,['GLS2'],0.42929047838551226,0,0,1
132,FGF23 signaling in hypophosphatemic rickets and related disorders WP4790,0.18556427130212466,5.5131578947368425,9.28610944744807,['FAM20C'],0.42929047838551226,0,0,1
133,Mammary gland development pathway - Puberty (Stage 2 of 4) WP2814,0.18556427130212466,5.5131578947368425,9.28610944744807,['EGF'],0.42929047838551226,0,0,1
134,RAS and bradykinin pathways in COVID-19 WP4969,0.18556427130212466,5.5131578947368425,9.28610944744807,['SERPING1'],0.42929047838551226,0,0,1
135,Amyotrophic lateral sclerosis (ALS) WP2447,0.19392574924945938,2.5762376237623763,4.225750866613691,"['NEFL', 'NEFM']",0.4420366343186206,0,0,2
136,p38 MAPK Signaling Pathway WP400,0.19392574924945938,2.5762376237623763,4.225750866613691,"['HSPB1', 'HRAS']",0.4420366343186206,0,0,2
137,VEGFA-VEGFR2 Signaling Pathway WP3888,0.19802915910135147,1.3485766142555584,2.183805390889605,"['DNAJA1', 'PAK1', 'TMSB4X', 'RCAN2', 'CFL1', 'ARPC5L', 'HSPB1', 'CYCS', 'TMSB10', 'HRAS', 'NDRG1', 'HSPA1A']",0.4480951775286055,0,0,12
138,IL-2 signaling pathway WP49,0.20320025164577663,2.4929202597679123,3.9726262977773836,"['SOCS3', 'HRAS']",0.4555291464964662,0,0,2
139,Ethanol metabolism resulting in production of ROS by CYP2E1 WP4269,0.20620256885771346,4.823601973684211,7.615967064795545,['PRKCQ'],0.4555291464964662,0,0,1
140,MFAP5-mediated ovarian cancer cell motility and invasiveness WP3301,0.20620256885771346,4.823601973684211,7.615967064795545,['PRKCQ'],0.4555291464964662,0,0,1
141,Non-small cell lung cancer WP4255,0.20719228921290883,1.966550679088562,3.0955631239356043,"['EGF', 'CYCS', 'HRAS']",0.4555291464964662,0,0,3
142,G13 Signaling Pathway WP524,0.21252330434490818,2.414810231023102,3.7398253684342775,"['CFL1', 'PAK3']",0.4607148555728779,0,0,2
143,Nephrotic syndrome WP4758,0.21252330434490818,2.414810231023102,3.7398253684342775,"['PLCE1', 'SYNPO']",0.4607148555728779,0,0,2
144,Nonalcoholic fatty liver disease WP4396,0.2196678142098385,1.5870218579234974,2.4053519188237096,"['COX8A', 'SOCS3', 'CYCS', 'IRS2', 'UQCRH']",0.4620471889477053,0,0,5
145,TCA cycle in senescence WP5050,0.22631955065648168,4.287280701754386,6.370073124268204,['MDH1'],0.4620471889477053,0,0,1
146,Computational Model of Aerobic Glycolysis WP4629,0.22631955065648168,4.287280701754386,6.370073124268204,['TPI1'],0.4620471889477053,0,0,1
147,FOXA2 pathway WP5066,0.22631955065648168,4.287280701754386,6.370073124268204,['IRS2'],0.4620471889477053,0,0,1
148,Ganglio Sphingolipid Metabolism WP1423,0.22631955065648168,4.287280701754386,6.370073124268204,['ST8SIA3'],0.4620471889477053,0,0,1
149,IL1 and megakaryocytes in obesity WP2865,0.22631955065648168,4.287280701754386,6.370073124268204,['IL1R1'],0.4620471889477053,0,0,1
150,Osteopontin Signaling WP1434,0.22631955065648168,4.287280701754386,6.370073124268204,['MAP3K14'],0.4620471889477053,0,0,1
151,Notch Signaling WP268,0.2312819629287246,2.2723742962531546,3.3270234146956517,"['HES1', 'HES5']",0.4620471889477053,0,0,2
152,PDGF Pathway WP2526,0.2312819629287246,2.2723742962531546,3.3270234146956517,"['PAK1', 'HRAS']",0.4620471889477053,0,0,2
153,Chemokine signaling pathway WP3929,0.2366078613946779,1.646285431540256,2.372875320083978,"['PAK1', 'GNG2', 'HRAS', 'CX3CL1']",0.4620471889477053,0,0,4
154,Pathways Regulating Hippo Signaling WP4540,0.24060871550867122,1.8121378311258278,2.5815412046068977,"['PRKAR1A', 'PRKAR2B', 'PRKCQ']",0.4620471889477053,0,0,3
155,Interleukin-11 Signaling Pathway WP2332,0.2407019813923534,2.207260726072607,3.143571240225972,"['SOCS3', 'HRAS']",0.4620471889477053,0,0,2
156,Tryptophan catabolism leading to NAD+ production WP4210,0.24592834250442377,3.858223684210526,5.411988528868204,['HAAO'],0.4620471889477053,0,0,1
157,Cell-type Dependent Selectivity of CCK2R Signaling WP3679,0.24592834250442377,3.858223684210526,5.411988528868204,['ITPR1'],0.4620471889477053,0,0,1
158,Type II diabetes mellitus WP1584,0.24592834250442377,3.858223684210526,5.411988528868204,['CACNA1A'],0.4620471889477053,0,0,1
159,Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291,0.24592834250442377,3.858223684210526,5.411988528868204,['SYTL4'],0.4620471889477053,0,0,1
160,Fatty acid transporters WP5061,0.24592834250442377,3.858223684210526,5.411988528868204,['FABP3'],0.4620471889477053,0,0,1
161,GPR40 Pathway WP3958,0.24592834250442377,3.858223684210526,5.411988528868204,['PLCE1'],0.4620471889477053,0,0,1
162,Hypertrophy Model WP516,0.24592834250442377,3.858223684210526,5.411988528868204,['IL1R1'],0.4620471889477053,0,0,1
163,Kynurenine Pathway and links to Cellular Senescence WP5044,0.24592834250442377,3.858223684210526,5.411988528868204,['HAAO'],0.4620471889477053,0,0,1
164,MAPK and NFkB signaling pathways inhibited by Yersinia YopJ WP3849,0.24592834250442377,3.858223684210526,5.411988528868204,['MAP3K14'],0.4620471889477053,0,0,1
165,RalA downstream regulated genes WP2290,0.24592834250442377,3.858223684210526,5.411988528868204,['HRAS'],0.4620471889477053,0,0,1
166,Glycogen Synthesis and Degradation WP500,0.25013934718843883,2.145764576457646,2.9734656407925653,"['HKDC1', 'CALM3']",0.4643305247210541,0,0,2
167,Phosphodiesterases in neuronal function WP4222,0.25013934718843883,2.145764576457646,2.9734656407925653,"['GRIN2A', 'PDE10A']",0.4643305247210541,0,0,2
168,ATM Signaling Network in Development and Disease  WP3878,0.25958716549704147,2.0875925430380877,2.8154582684675336,"['HSPB1', 'CDK5R1']",0.4776915097638115,0,0,2
169,Pathways in clear cell renal cell carcinoma WP4018,0.26107086290479015,1.7305525353365623,2.3240687221474166,"['TPI1', 'MDH1', 'ENO2']",0.4776915097638115,0,0,3
170,Cori Cycle WP1946,0.2650417409012115,3.507177033492823,4.6570679867471005,['TPI1'],0.4776915097638115,0,0,1
171,Cysteine and methionine catabolism WP4504,0.2650417409012115,3.507177033492823,4.6570679867471005,['SQOR'],0.4776915097638115,0,0,1
172,Pyrimidine metabolism and related diseases WP4225,0.2650417409012115,3.507177033492823,4.6570679867471005,['GLS2'],0.4776915097638115,0,0,1
173,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.26794262032643174,1.7049571484222827,2.245398599260754,"['EGF', 'HGF', 'HRAS']",0.4801283948045887,0,0,3
174,Osteoblast differentiation WP4787,0.2748352059620523,1.6801036567808811,2.169994349534795,"['WNT7B', 'SMAD9', 'PRKCQ']",0.4885466030287572,0,0,3
175,Envelope proteins and their potential roles in EDMD physiopathology WP4535,0.2784882476523968,1.9801980198019802,2.531444394534359,"['CFL1', 'HRAS']",0.4885466030287572,0,0,2
176,Modulators of TCR signaling and T cell activation WP5072,0.2784882476523968,1.9801980198019802,2.531444394534359,"['PRKCQ', 'MAP3K14']",0.4885466030287572,0,0,2
177,Pancreatic adenocarcinoma pathway WP4263,0.2817458859205723,1.6559602649006622,2.09768721522109,"['PAK1', 'EGF', 'PAK3']",0.4885466030287572,0,0,3
178,STING pathway in Kawasaki-like disease and COVID-19 WP4961,0.2836722211134719,3.2146381578947367,4.0502378868322,['ITPR1'],0.4885466030287572,0,0,1
179,Phytochemical activity on NRF2 transcriptional activation WP3,0.2836722211134719,3.2146381578947367,4.0502378868322,['CEBPB'],0.4885466030287572,0,0,1
180,Riboflavin and CoQ disorders WP5037,0.2836722211134719,3.2146381578947367,4.0502378868322,['RFK'],0.4885466030287572,0,0,1
181,Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.2973565653543252,1.883281011027932,2.284087097256726,"['SOCS3', 'HSPB1']",0.5092847251924907,0,0,2
182,Nanomaterial induced apoptosis WP2507,0.3018319453554548,2.9671052631578947,3.554250558300027,['CYCS'],0.5121508120231227,0,0,1
183,TNF-alpha signaling pathway WP231,0.3025599907850189,1.587498866007439,1.8978163252787499,"['RFK', 'HRAS', 'MAP3K14']",0.5121508120231227,0,0,3
184,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.30398628842662767,1.4584090766626967,1.7366336883312998,"['TRIP10', 'IRS2', 'MAP3K14', 'HRAS']",0.5121508120231227,0,0,4
185,Interferon type I signaling pathways WP585,0.31614825310140116,1.7953795379537953,2.067458570614957,"['SOCS3', 'IRS2']",0.5213429413901177,0,0,2
186,Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.31614825310140116,1.7953795379537953,2.067458570614957,"['IRF7', 'PIN1']",0.5213429413901177,0,0,2
187,Sleep regulation WP3591,0.319532770529427,2.754934210526316,3.143091884507585,['GRIN2A'],0.5213429413901177,0,0,1
188,TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc) WP2453,0.319532770529427,2.754934210526316,3.143091884507585,['MDH1'],0.5213429413901177,0,0,1
189,Cardiac Progenitor Differentiation WP2406,0.319532770529427,2.754934210526316,3.143091884507585,['THY1'],0.5213429413901177,0,0,1
190,Mitochondrial complex III assembly WP4921,0.319532770529427,2.754934210526316,3.143091884507585,['UQCRH'],0.5213429413901177,0,0,1
191,Hepatitis B infection WP4666,0.32695957252573776,1.4048927816369676,1.5705559783243614,"['IRF7', 'CYCS', 'HRAS', 'YWHAZ']",0.5306673690208309,0,0,4
192,DNA damage response (only ATM dependent) WP710,0.33040946434439833,1.5045153521974715,1.666134291990305,"['BCL6', 'WNT7B', 'HRAS']",0.5326721392913644,0,0,3
193,Cardiac Hypertrophic Response WP2795,0.33482388700440296,1.7152915291529154,1.876787248637728,"['EGF', 'MAP3K14']",0.5326721392913644,0,0,2
194,Rett syndrome causing genes WP4312,0.33482388700440296,1.7152915291529154,1.876787248637728,"['GRIN2A', 'GABRD']",0.5326721392913644,0,0,2
195,"Oligodendrocyte specification and differentiation, leading to myelin components for CNS WP4304",0.3367862558100239,2.5710526315789473,2.7980940765331193,['PLP1'],0.5326721392913644,0,0,1
196,"Relationship between inflammation, COX-2 and EGFR WP4483",0.3367862558100239,2.5710526315789473,2.7980940765331193,['HRAS'],0.5326721392913644,0,0,1
197,Striated Muscle Contraction Pathway WP383,0.35360367020052863,2.41015625,2.5055467848295487,['ACTA2'],0.539985900306226,0,0,1
198,Canonical and non-canonical Notch signaling WP3845,0.35360367020052863,2.41015625,2.5055467848295487,['HES1'],0.539985900306226,0,0,1
199,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,0.35360367020052863,2.41015625,2.5055467848295487,['HRAS'],0.539985900306226,0,0,1
200,Kallmann's Syndrome WP5074,0.35360367020052863,2.41015625,2.5055467848295487,['PRKCQ'],0.539985900306226,0,0,1
201,Metabolism of Spingolipids in ER and Golgi apparatus WP4142,0.35360367020052863,2.41015625,2.5055467848295487,['UGCG'],0.539985900306226,0,0,1
202,Ovarian infertility WP34,0.35360367020052863,2.41015625,2.5055467848295487,['CEBPB'],0.539985900306226,0,0,1
203,Purine metabolism and related disorders WP4224,0.35360367020052863,2.41015625,2.5055467848295487,['GRM5'],0.539985900306226,0,0,1
204,Cell cycle WP179,0.3582323945086864,1.4297277409860192,1.4677204059647566,"['YWHAZ', 'YWHAG', 'YWHAH']",0.5415404676949134,0,0,3
205,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.3593108158485749,1.2464127737620023,1.2757875853184464,"['GNG2', 'EGF', 'HGF', 'IRS2', 'OSMR', 'HRAS']",0.5415404676949134,0,0,6
206,Notch Signaling Pathway Netpath WP61,0.3625435336818078,1.6076732673267327,1.6311625296515664,"['HES1', 'HES5']",0.5415404676949134,0,0,2
207,Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,0.36999599974779185,2.268188854489164,2.255176447588322,['IRF7'],0.5415404676949134,0,0,1
208,Ebstein-Barr virus LMP1 signaling WP262,0.36999599974779185,2.268188854489164,2.255176447588322,['MAP3K14'],0.5415404676949134,0,0,1
209,Host-pathogen interaction of human coronaviruses - autophagy WP4863,0.36999599974779185,2.268188854489164,2.255176447588322,['MAP1LC3A'],0.5415404676949134,0,0,1
210,p53 transcriptional gene network WP4963,0.3716895351831676,1.5747289014615746,1.5585034554771409,"['GLS2', 'CX3CL1']",0.5415404676949134,0,0,2
211,Primary focal segmental glomerulosclerosis (FSGS) WP2572,0.3716895351831676,1.5747289014615746,1.5585034554771409,"['PLCE1', 'SYNPO']",0.5415404676949134,0,0,2
212,Electron Transport Chain (OXPHOS system in mitochondria) WP111,0.3720907084484405,1.3950371020505865,1.3791582519932823,"['COX8A', 'SLC25A4', 'UQCRH']",0.5415404676949134,0,0,3
213,Gastrin signaling pathway WP4659,0.3720907084484405,1.3950371020505865,1.3791582519932823,"['PAK1', 'PRKCQ', 'HRAS']",0.5415404676949134,0,0,3
214,White fat cell differentiation WP4149,0.3859739546319343,2.1419956140350878,2.0391485232381727,['CEBPB'],0.5488620455775212,0,0,1
215,"GPCRs, Other WP117",0.3859739546319343,2.1419956140350878,2.0391485232381727,['GRM1'],0.5488620455775212,0,0,1
216,Hippo-Yap signaling pathway WP4537,0.3859739546319343,2.1419956140350878,2.0391485232381727,['NDRG1'],0.5488620455775212,0,0,1
217,NAD Metabolism in Oncogene-Induced Senescence and Mitochondrial Dysfunction-Associated Senescence WP5046,0.3859739546319343,2.1419956140350878,2.0391485232381727,['MDH1'],0.5488620455775212,0,0,1
218,Prostaglandin Synthesis and Regulation WP98,0.3859739546319343,2.1419956140350878,2.0391485232381727,['S100A6'],0.5488620455775212,0,0,1
219,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.3961626832706415,1.2653994880453134,1.1716717728231452,"['CFL1', 'IRS2', 'HRAS', 'CDK5R1']",0.5544453016641199,0,0,4
220,Apoptosis WP254,0.398798333849722,1.4834983498349834,1.363779170812758,"['IRF7', 'CYCS']",0.5544453016641199,0,0,2
221,Sphingolipid Metabolism (general overview) WP4725,0.40154797601869524,2.0290858725761773,1.8513952936920022,['UGCG'],0.5544453016641199,0,0,1
222,Cell migration and invasion through p75NTR WP4561,0.40154797601869524,2.0290858725761773,1.8513952936920022,['PAK1'],0.5544453016641199,0,0,1
223,Nanoparticle triggered autophagic cell death WP2509,0.40154797601869524,2.0290858725761773,1.8513952936920022,['MAP1LC3A'],0.5544453016641199,0,0,1
224,Ebola Virus Pathway on Host WP4217,0.41326778275897974,1.3003199642830567,1.1490401047274261,"['SOCS3', 'PAK1', 'IRF7']",0.5544453016641199,0,0,3
225,Toll-like Receptor Signaling Pathway WP75,0.416567001752252,1.4283094976164283,1.2507819989206632,"['TOLLIP', 'IRF7']",0.5544453016641199,0,0,2
226,Sphingolipid Metabolism (integrated pathway) WP4726,0.4167282428636772,1.9274671052631578,1.6871523673554742,['UGCG'],0.5544453016641199,0,0,1
227,TLR4 Signaling and Tolerance WP3851,0.4167282428636772,1.9274671052631578,1.6871523673554742,['IRF7'],0.5544453016641199,0,0,1
228,Tryptophan metabolism WP465,0.4167282428636772,1.9274671052631578,1.6871523673554742,['HAAO'],0.5544453016641199,0,0,1
229,Wnt signaling in kidney disease WP4150,0.4167282428636772,1.9274671052631578,1.6871523673554742,['WNT7B'],0.5544453016641199,0,0,1
230,EPO Receptor Signaling WP581,0.4167282428636772,1.9274671052631578,1.6871523673554742,['IRS2'],0.5544453016641199,0,0,1
231,miRNAs involvement in the immune response in sepsis WP4329,0.4167282428636772,1.9274671052631578,1.6871523673554742,['IRF7'],0.5544453016641199,0,0,1
232,NRF2-ARE regulation WP4357,0.4167282428636772,1.9274671052631578,1.6871523673554742,['CEBPB'],0.5544453016641199,0,0,1
233,SARS-CoV-2 mitochondrial interactions WP5038,0.4167282428636772,1.9274671052631578,1.6871523673554742,['IRF7'],0.5544453016641199,0,0,1
234,Epithelial to mesenchymal transition in colorectal cancer WP4239,0.4268146401694142,1.271523178807947,1.082581774366361,"['PAK1', 'WNT7B', 'HRAS']",0.559718202186356,0,0,3
235,Type II interferon signaling (IFNG) WP619,0.4315246784598036,1.8355263157894737,1.5426324422102315,['SOCS3'],0.559718202186356,0,0,1
236,Vitamin A and carotenoid metabolism WP716,0.4315246784598036,1.8355263157894737,1.5426324422102315,['RBP2'],0.559718202186356,0,0,1
237,Hematopoietic Stem Cell Differentiation WP2849,0.4315246784598036,1.8355263157894737,1.5426324422102315,['TRIM29'],0.559718202186356,0,0,1
238,Overview of leukocyte-intrinsic Hippo pathway functions WP4542,0.4315246784598036,1.8355263157894737,1.5426324422102315,['NDRG1'],0.559718202186356,0,0,1
239,Oxidation by Cytochrome P450 WP43,0.4315246784598036,1.8355263157894737,1.5426324422102315,['CYP39A1'],0.559718202186356,0,0,1
240,Endometrial cancer WP4155,0.4340683934799817,1.377062706270627,1.1492320449258202,"['EGF', 'HRAS']",0.560671674911643,0,0,2
241,Head and Neck Squamous Cell Carcinoma WP4674,0.4427132217828185,1.3527879103699845,1.1022963307377958,"['FKBP1A', 'HRAS']",0.5694651400525882,0,0,2
242,Aryl Hydrocarbon Receptor Pathway WP2873,0.44594695672640783,1.7519437799043063,1.414791423693881,['HES1'],0.5712543660544893,0,0,1
243,Sphingolipid pathway WP1422,0.4600045087006121,1.675629290617849,1.3011579610538802,['UGCG'],0.5796804784438608,0,0,1
244,Nanoparticle-mediated activation of receptor signaling WP2643,0.4600045087006121,1.675629290617849,1.3011579610538802,['HRAS'],0.5796804784438608,0,0,1
245,Neovascularisation processes WP4331,0.4600045087006121,1.675629290617849,1.3011579610538802,['SMAD9'],0.5796804784438608,0,0,1
246,Oxysterols derived from cholesterol WP4545,0.4600045087006121,1.675629290617849,1.3011579610538802,['CYP39A1'],0.5796804784438608,0,0,1
247,Retinoblastoma gene in cancer WP2446,0.46820084327275124,1.284818481848185,0.9749946843512131,"['H2AFZ', 'STMN1']",0.5876204915568943,0,0,2
248,BDNF-TrkB Signaling WP3676,0.4737065283372991,1.605674342105263,1.1997073428976819,['HRAS'],0.5897551156006534,0,0,1
249,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities WP3844,0.4737065283372991,1.605674342105263,1.1997073428976819,['HRAS'],0.5897551156006534,0,0,1
250,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.47654209196399916,1.2636476762430342,0.9366146771456986,"['PRKCQ', 'HRAS']",0.590912194035359,0,0,2
251,Folate Metabolism WP176,0.5000795973605098,1.481907894736842,1.02694438594846,['RFK'],0.6139737378493656,0,0,1
252,Intraflagellar transport proteins binding to dynein WP4532,0.5000795973605098,1.481907894736842,1.02694438594846,['DYNLT3'],0.6139737378493656,0,0,1
253,Leptin signaling pathway WP2034,0.5010817925028693,1.2041047854785478,0.8320194683030396,"['SOCS3', 'HRAS']",0.6139737378493656,0,0,2
254,MicroRNAs in cardiomyocyte hypertrophy WP1544,0.5090963447319934,1.1854785478547856,0.8003379038547849,"['EGF', 'MAP3K14']",0.6213380585311731,0,0,2
255,Glioblastoma signaling pathways WP2261,0.5170265013547312,1.1674167416741674,0.7700994655716142,"['PRKCQ', 'HRAS']",0.6285420212547712,0,0,2
256,Fatty acid beta-oxidation WP143,0.5251351987986601,1.3758223684210527,0.8861665381424284,['TPI1'],0.6334315627532475,0,0,1
257,PDGFR-beta pathway WP3972,0.5251351987986601,1.3758223684210527,0.8861665381424284,['HRAS'],0.6334315627532475,0,0,1
258,B Cell Receptor Signaling Pathway WP23,0.5326302208040492,1.132886818093574,0.7136369748169977,"['BCL6', 'HRAS']",0.6375110750936497,0,0,2
259,Wnt signaling pathway and pluripotency WP399,0.5326302208040492,1.132886818093574,0.7136369748169977,"['WNT7B', 'PRKCQ']",0.6375110750936497,0,0,2
260,CAMKK2  Pathway WP4874,0.5371895808542921,1.3282667876588021,0.825390573593418,['MAP1LC3A'],0.638041264616209,0,0,1
261,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling WP3850,0.5371895808542921,1.3282667876588021,0.825390573593418,['MAP1LC3A'],0.638041264616209,0,0,1
262,PI3K-Akt signaling pathway WP4172,0.542856075897828,1.0240248226950355,0.6255880773815374,"['GNG2', 'EGF', 'HGF', 'OSMR', 'HRAS']",0.6423106241539187,0,0,5
263,TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036,0.5603909722939169,1.2423599320882852,0.7194761970427801,['MAP3K14'],0.6530872233500535,0,0,1
264,Hepatitis C and Hepatocellular Carcinoma WP3646,0.5603909722939169,1.2423599320882852,0.7194761970427801,['UCHL1'],0.6530872233500535,0,0,1
265,Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.5603909722939169,1.2423599320882852,0.7194761970427801,['IFITM3'],0.6530872233500535,0,0,1
266,MAPK Cascade WP422,0.5603909722939169,1.2423599320882852,0.7194761970427801,['HRAS'],0.6530872233500535,0,0,1
267,22q11.2 copy number variation syndrome WP4657,0.5627926851907533,1.0695819581958195,0.6148427187674612,"['ACTA2', 'HES1']",0.6534297093975038,0,0,2
268,Target Of Rapamycin (TOR) Signaling WP1471,0.5715531750911739,1.2034333881578947,0.6731979359846427,['FKBP1A'],0.6562277195491255,0,0,1
269,Ferroptosis WP4313,0.5715531750911739,1.2034333881578947,0.6731979359846427,['MAP1LC3A'],0.6562277195491255,0,0,1
270,Phosphoinositides metabolism WP4971,0.5715531750911739,1.2034333881578947,0.6731979359846427,['PLCE1'],0.6562277195491255,0,0,1
271,Integrated breast cancer pathway WP1984,0.5951913034099185,0.9783084521270625,0.507617261124916,"['ITPKC', 'PAK1', 'RASGEF1A']",0.6808461404320102,0,0,3
272,IL-6 signaling pathway WP364,0.6033730121130906,1.1,0.5557416475815162,['SOCS3'],0.6849149123662263,0,0,1
273,SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,0.6033730121130906,1.1,0.5557416475815162,['IRF7'],0.6849149123662263,0,0,1
274,Regulation of toll-like receptor signaling pathway WP1449,0.6053764064140194,0.9867986798679867,0.4952790483828487,"['TOLLIP', 'IRF7']",0.6849149123662263,0,0,2
275,7q11.23 copy number variation syndrome WP4932,0.6188569901311393,0.961963696369637,0.46162816474416357,"['SNAP25', 'CFL1']",0.6950092091891904,0,0,2
276,Endochondral Ossification with Skeletal Dysplasias WP4808,0.6232663230793385,1.0403627311522048,0.4918641138581006,['SLC38A2'],0.6950092091891904,0,0,1
277,Endochondral Ossification WP474,0.6232663230793385,1.0403627311522048,0.4918641138581006,['SLC38A2'],0.6950092091891904,0,0,1
278,IL-3 signaling pathway WP286,0.6232663230793385,1.0403627311522048,0.4918641138581006,['HRAS'],0.6950092091891904,0,0,1
279,Cytosolic DNA-sensing pathway WP4655,0.6421649636643099,0.9868421052631579,0.43708229166190765,['IRF7'],0.7135166262936776,0,0,1
280,Endoplasmic reticulum stress response in coronavirus infection WP4861,0.651256873445267,0.9620888157894737,0.4125928774815569,['MAP1LC3A'],0.7184684368969138,0,0,1
281,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway WP4577,0.651256873445267,0.9620888157894737,0.4125928774815569,['MAP1LC3A'],0.7184684368969138,0,0,1
282,PPAR signaling pathway WP3942,0.660118512170618,0.9385430038510911,0.38981059961402187,['FABP3'],0.7256621942301119,0,0,1
283,Selenium Micronutrient Network WP15,0.6687556931850658,0.9161184210526315,0.3685878494609617,['RFK'],0.7299798059414451,0,0,1
284,Glucocorticoid Receptor Pathway WP2880,0.6687556931850658,0.9161184210526315,0.3685878494609617,['ENC1'],0.7299798059414451,0,0,1
285,RANKL/RANK signaling pathway WP2018,0.6771740834891344,0.8947368421052632,0.3487924890748231,['TNFRSF11B'],0.7365753188829182,0,0,1
286,ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,0.6853792076161169,0.8743271531100478,0.33030594024503956,['WNT7B'],0.7428935467167701,0,0,1
287,Translation Factors WP107,0.7087681627105974,0.8183090705487122,0.28168391102221757,['EEF1A2'],0.7602703475442394,0,0,1
288,DNA damage response WP707,0.7087681627105974,0.8183090705487122,0.28168391102221757,['CYCS'],0.7602703475442394,0,0,1
289,Kit receptor signaling pathway WP304,0.7087681627105974,0.8183090705487122,0.28168391102221757,['HRAS'],0.7602703475442394,0,0,1
290,AGE/RAGE pathway WP2324,0.7233896515524544,0.7847744360902256,0.25411566368047167,['CYCS'],0.7706212782861198,0,0,1
291,miRNA regulation of DNA damage response WP1530,0.7233896515524544,0.7847744360902256,0.25411566368047167,['CYCS'],0.7706212782861198,0,0,1
292,Acute viral myocarditis WP4298,0.7372793400217875,0.7538699690402477,0.2297708484401368,['CYCS'],0.7827280664614867,0,0,1
293,Ciliary landscape WP4352,0.7428671637198598,0.7908346747953557,0.23506614390460925,"['DYNLT3', 'CDH23', 'NEFL', 'NEFM']",0.7844489276243064,0,0,4
294,3q29 copy number variation syndrome WP4906,0.7439612410372454,0.7393092105263158,0.2186627799807621,['DYNLT3'],0.7844489276243064,0,0,1
295,LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,0.7504737398993414,0.7252979145978153,0.20819721509925232,['WNT7B'],0.7859691194891751,0,0,1
296,Pathways affected in adenoid cystic carcinoma WP3651,0.7504737398993414,0.7252979145978153,0.20819721509925232,['HRAS'],0.7859691194891751,0,0,1
297,Ectoderm Differentiation WP2858,0.7583906454101343,0.7313531353135313,0.20226058239839867,"['TNFRSF11B', 'SNCA']",0.7915861955459315,0,0,2
298,MECP2 and Associated Rett Syndrome WP3584,0.763007547140157,0.6988038277511962,0.18901759997151332,['BCL6'],0.7937326832666062,0,0,1
299,Sterol regulatory element-binding proteins (SREBP) signaling WP1982,0.7916643206252802,0.640296052631579,0.14958456451701863,['MDH1'],0.8207890949626652,0,0,1
300,16p11.2 proximal deletion syndrome WP4949,0.8021351260288804,0.6195352292020373,0.13659401154380343,['SEZ6L2'],0.8233837386389169,0,0,1
301,Chromosomal and microsatellite instability in colorectal cancer  WP4216,0.8021351260288804,0.6195352292020373,0.13659401154380343,['CYCS'],0.8233837386389169,0,0,1
302,DNA IR-damage and cellular response via ATR WP4016,0.8021351260288804,0.6195352292020373,0.13659401154380343,['BCL6'],0.8233837386389169,0,0,1
303,Amino Acid metabolism WP3925,0.8215290745117871,0.5817882775119617,0.11437256489785956,['MDH1'],0.8405082940549637,0,0,1
304,Corticotropin-releasing hormone signaling pathway WP2355,0.8260738798291201,0.5730557737627652,0.10949437789611081,['PRKCQ'],0.8423779695625895,0,0,1
305,Small cell lung cancer WP4658,0.8348203113796397,0.556350114416476,0.10044276714967464,['CYCS'],0.8485058902547158,0,0,1
306,Wnt signaling WP428,0.8548156837445253,0.5185366287339972,0.08134253389944815,['WNT7B'],0.865989744969944,0,0,1
307,Androgen receptor signaling pathway WP138,0.8621209389480682,0.5048043628808865,0.07489263279892179,['LIMK2'],0.8705455735306226,0,0,1
308,Thermogenesis WP4321,0.8907163161433552,0.4510061919504644,0.05219462654890134,['HRAS'],0.8935988932182529,0,0,1
309,Cytoplasmic Ribosomal Proteins WP477,0.8907163161433552,0.4510061919504644,0.05219462654890134,['RPL35'],0.8935988932182529,0,0,1
310,Mesodermal commitment pathway WP2857,0.9198606761478343,0.3948046663049376,0.03297924163270188,['PRKAR1A'],0.9198606761478343,0,0,1
